Literature DB >> 19713358

Functional characterization of human cytochrome P450 2S1 using a synthetic gene-expressed protein in Escherichia coli.

Peter H Bui1, Oliver Hankinson.   

Abstract

Human cytochrome P450 2S1 was recently identified and shown to be inducible by 2,3,7,8-tetrachlorodibenzo-p-dioxin and hypoxia. It is highly expressed in epithelial cells of tissues that are exposed to the environment and in many tumors of epithelial origin. The biological function of CYP2S1 has not yet been determined, although its possible role in carcinogen metabolism has been suggested. In this report, we investigated its ability to metabolize carcinogens. To obtain a large quantity of active enzyme for substrate screening, we overexpressed CYP2S1 in Escherichia coli (200 nM culture), using a synthetic gene approach. High-level expression allowed us to achieve purification of CYP2S1 with high specific content and purity (16 nmol/mg). Despite high-level expression, we found that CYP2S1 was not readily reduced by cytochrome P450 reductase, and thus no activity was found using NADPH. However, the oxidative activity of CYP2S1 was supported by cumene hydroperoxide or H(2)O(2), such that CYP2S1 oxidized many important environmental carcinogens, including benzo[a]pyrene, 9,10-dihydro-benzo[a]pyrene, 7,12-dimethylbenz[a]anthracene, benzo[a]pyrene-7,8-dihydrodiol, aflatoxin B1, naphthalene, and styrene, with high turnover. Most substrates tested were converted to detoxification products, except in the case of benzo[a]pyrene-7,8-dihydrodiol, which was converted into the very potent carcinogenic metabolite 7,8-dihydrodiol-trans-9,10-epoxide at a relatively efficient rate (K(m) = 12.4 +/- 2 microM, turnover = 2.3 min(-1)). This metabolite formation was also supported both in vitro and in vivo by fatty acid hydroperoxides described in the accompanying report (p. 1044). Together, these data indicate that CYP2S1 contributes to the metabolism of environmental carcinogens via an NADPH independent activity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19713358      PMCID: PMC2774995          DOI: 10.1124/mol.109.057752

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  58 in total

1.  Identification of a novel dioxin-inducible cytochrome P450.

Authors:  Steven P Rivera; Sirkku T Saarikoski; Oliver Hankinson
Journal:  Mol Pharmacol       Date:  2002-02       Impact factor: 4.436

2.  Studies on hydroperoxide-dependent substrate hydroxylation by purified liver microsomal cytochrome P-450.

Authors:  G D Nordblom; R E White; M J Coon
Journal:  Arch Biochem Biophys       Date:  1976-08       Impact factor: 4.013

3.  Purification and crystallization of N-terminally truncated forms of microsomal cytochrome P450 2C5.

Authors:  Michael R Wester; C David Stout; Eric F Johnson
Journal:  Methods Enzymol       Date:  2002       Impact factor: 1.600

4.  Residue 285 in cytochrome P450 2B4 lacking the NH(2)-terminal hydrophobic sequence has a role in the functional association of NADPH-cytochrome P450 reductase.

Authors:  J Schulze; K Tschöp; M Lehnerer; P Hlavica
Journal:  Biochem Biophys Res Commun       Date:  2000-04-21       Impact factor: 3.575

5.  Mutagenic and cytotoxic activity of benzol[a]pyrene 4,5-, 7,8-, and 9,10-oxides and the six corresponding phenols.

Authors:  A W Wood; R L Goode; R L Chang; W Levin; A H Conney; H Yagi; P M Dansette; D M Jerina
Journal:  Proc Natl Acad Sci U S A       Date:  1975-08       Impact factor: 11.205

Review 6.  Clinical importance of the cytochromes P450.

Authors:  Daniel W Nebert; David W Russell
Journal:  Lancet       Date:  2002-10-12       Impact factor: 79.321

7.  Profiling cytochrome P450 expression in ovarian cancer: identification of prognostic markers.

Authors:  Diane Downie; Morag C E McFadyen; Patrick H Rooney; Margaret E Cruickshank; David E Parkin; Iain D Miller; Colin Telfer; William T Melvin; Graeme I Murray
Journal:  Clin Cancer Res       Date:  2005-10-15       Impact factor: 12.531

8.  Cutaneous expression of cytochrome P450 CYP2S1: individuality in regulation by therapeutic agents for psoriasis and other skin diseases.

Authors:  Gillian Smith; C Roland Wolf; Yusuf Y Deeni; Robert S Dawe; Alan T Evans; Muriel M Comrie; James Ferguson; Sally H Ibbotson
Journal:  Lancet       Date:  2003-04-19       Impact factor: 79.321

9.  Some properties of a detergent-solubilized NADPH-cytochrome c(cytochrome P-450) reductase purified by biospecific affinity chromatography.

Authors:  Y Yasukochi; B S Masters
Journal:  J Biol Chem       Date:  1976-09-10       Impact factor: 5.157

10.  Target cells for cytochrome p450-catalysed irreversible binding of 7,12-dimethylbenz[a]anthracene (DMBA) in rodent adrenal glands.

Authors:  Orjan Lindhe; Lizette Granberg; Ingvar Brandt
Journal:  Arch Toxicol       Date:  2002-06-25       Impact factor: 5.153

View more
  21 in total

Review 1.  Contributions of human enzymes in carcinogen metabolism.

Authors:  Slobodan Rendic; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2012-05-10       Impact factor: 3.739

2.  Heterologous expression of human cytochromes P450 2D6 and CYP3A4 in Escherichia coli and their functional characterization.

Authors:  Yan Pan; Badrul Amini Abd-Rashid; Zakiah Ismail; Rusli Ismail; Joon Wah Mak; Chin Eng Ong
Journal:  Protein J       Date:  2011-12       Impact factor: 2.371

Review 3.  Characterizing proteins of unknown function: orphan cytochrome p450 enzymes as a paradigm.

Authors:  F Peter Guengerich; Zhongmei Tang; S Giovanna Salamanca-Pinzón; Qian Cheng
Journal:  Mol Interv       Date:  2010-06

Review 4.  Xenobiotica-metabolizing enzymes in the skin of rat, mouse, pig, guinea pig, man, and in human skin models.

Authors:  F Oesch; E Fabian; Robert Landsiedel
Journal:  Arch Toxicol       Date:  2018-06-18       Impact factor: 5.153

Review 5.  Orphans in the human cytochrome P450 superfamily: approaches to discovering functions and relevance in pharmacology.

Authors:  F Peter Guengerich; Qian Cheng
Journal:  Pharmacol Rev       Date:  2011-07-07       Impact factor: 25.468

Review 6.  Peroxygenase reactions catalyzed by cytochromes P450.

Authors:  Osami Shoji; Yoshihito Watanabe
Journal:  J Biol Inorg Chem       Date:  2014-02-06       Impact factor: 3.358

7.  Efficient hypoxic activation of the anticancer agent AQ4N by CYP2S1 and CYP2W1.

Authors:  Clinton R Nishida; Melody Lee; Paul R Ortiz de Montellano
Journal:  Mol Pharmacol       Date:  2010-06-21       Impact factor: 4.436

8.  Fatty acid hydroperoxides support cytochrome P450 2S1-mediated bioactivation of benzo[a]pyrene-7,8-dihydrodiol.

Authors:  Peter H Bui; Erin L Hsu; Oliver Hankinson
Journal:  Mol Pharmacol       Date:  2009-08-27       Impact factor: 4.436

9.  Reduction of aromatic and heterocyclic aromatic N-hydroxylamines by human cytochrome P450 2S1.

Authors:  Kai Wang; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2013-05-29       Impact factor: 3.739

Review 10.  Cytochromes p450 and skin cancer: role of local endocrine pathways.

Authors:  Andrzej T Slominski; Michal A Zmijewski; Igor Semak; Blazej Zbytek; Alexander Pisarchik; Wei Li; Jordan Zjawiony; Robert C Tuckey
Journal:  Anticancer Agents Med Chem       Date:  2014-01       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.